In our previous study, doxorubicin-selected ovarian cancer cells demonstrated increased expression of NRF2 and its target genes for GSH synthesis, and NRF2 inhibition in this resistant cell line could restore doxorubicin sensitivity [137]. Here, NFE2L2 is linked to ovarian cancer.